Furthermore, we examined CASC9 expression in developing resistance to EGFR-TKIs in advanced NSCLC patients, which were divided into two groups (Supplementary Table S1): before EGFR-TKI treatment (defined as the BT group) and acquired resistance to EGFR-TKIs (defined as the AR group). Here, CASC9 is linked to non-small cell lung carcinoma.